Últimas noticias sobre Chord Energy (NASDAQ:CHRD) Bolsa

Chord Energy

Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.

Long Ideas

News

Markets

Media

Trading Ideas

CHRD

LRCX

REKR

SOUN

Jim Cramer llama a SoundHound AI una acción meme, su opinión sobre Lam Research y su favorita de energía, Enterprise Products Partners.

SoundHound AI y las recomendaciones de Cramer: ¿Inversión inteligente o especulación?

Chord Energy Corp

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 5.04%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and cut the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On April 14, Bristol Myers Squibb announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="913" height="853" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32.png" alt="" class="wp-image-879019" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32-768x718.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 6.35%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 69%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and lowered the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">VTRS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="913" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33.png" alt="" class="wp-image-879022" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33-768x708.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul>
<li>Dividend Yield: 4.15%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $125 to $115 on Feb. 5, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On April 15, Merck and privately held Cyprumed GmbH signed a non-exclusive license and option agreement on Tuesday to develop oral formulations of Merck&#8217;s peptides using Cyprumed&#8217;s drug delivery technology.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13.png" alt="" class="wp-image-879028" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

VTRS

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell sharply in today's pre-market trading  following a report indicating the company postponed the US debut of an affordable version of its <a href="https://www.benzinga.com/quote/TSLA">Model Y SUV</a>.
Tesla shares dipped 3.9% to $232.08 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>American Assets Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAT#NYSE">AAT</a>) shares dipped 58% to $8.01 in pre-market trading. American Assets Trust will announce its first quarter earnings after the market closes on Tuesday, April 29.</li>
<li>Viavi Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) tumbled 44.2% to $5.50 in pre-market trading.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) fell 12% to $7.25 in pre-market trading after gaining around 44% on Thursday.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares slipped 8.3% to $15.01 in pre-market trading.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares fell 7% to $12.51 in pre-market trading.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) declined 6.3% to $19.11 in pre-market trading. Concentra&#xAE; Group Holdings Parent will release the financial results for its first quarter on Wednesday, May 7, after the closing bell.</li>
<li>First Financial Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) fell 5.1% to $31.00 in pre-market trading. Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained First Finl Bankshares with a Market Perform and lowered the price target from $38 to $36.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 3.1% to $98.36 in pre-market trading following a 3% decline on Thursday.</li>
<li>MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) slipped 3% to $8.50 in pre-market trading.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) declined 2.8% to $7.67 in pre-market trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) slipped 2.3% to $192.51 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Movers

AAPL

CGEM

EWTX

FFIN

MTAL

NVDA

TSLA

VIAV

Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Seaport Global analyst Michael Harrison reiterates Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) from Neutral to Neutral.

Reiteration

Seaport Global Reiterates Neutral on Lindeto Neutral

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21070610/Epiworldj-900x600-1.png" alt="" class="wp-image-11062" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21070610/Epiworldj-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21070610/Epiworldj-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21070610/Epiworldj-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Under pressure from falling prices, the heavily subsidized maker of advanced wafers for automotive chips is seeking an IPO boost from investors
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>The company's revenue fell 14.4% last year but its net profit rose 36%</li>
<li>Nearly 68% of Epiworld's profit came from government subsidies</li>
</ul>
The global boom in electric cars and solar panels is being driven by high-tech chips that can operate under high temperature and pressure conditions.
And the makers of advanced microchip wafers are also feeling the heat as they battle it out for market share and investor cash.
A leading Chinese wafer foundry,&nbsp;Epiworld International Co. Ltd., has&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107286/documents/sehk25040801378.pdf">filed</a>&nbsp;to list its shares on the Hong Kong Stock Exchange, looking to invest the proceeds in technical knowhow and productive capacity as it seeks to fend off competitors and bolster its global business.
The company is following in the footsteps ofHong Kong-listed&nbsp;InnoScience&nbsp;(2577.HK)and IPO applicant&nbsp;Guangdong Tianyu Semiconductor&nbsp;in seeking a funding boost from the equity market, as the industry battles mounting pressure from consolidation and oversupply.
Third-generation semiconductors used in electric cars, consumer electronics, industrial settings and aerospace systems are based either on gallium nitride (GaN) or silicon carbide (SiC) wafers, which offer higher power capacity and resilience than silicon alone.&nbsp;Tesla&nbsp;(TSLA.US) blazed a trail by using silicon carbide in the inverters for its Model 3 sedans, and now more than70% of silicon carbide demand comes from the new energy vehicle industry.
Epiworld was founded in 2011 by a leading scientist in the field of silicon carbide science, Zhao Jianhui, who was honored for his work by the Institute of Electrical and Electronic Engineers (IEEE) in the United States.
The Chinese company has become the world's biggest foundry for silicon carbide wafers by annual sales, with a market share of 31.6% in 2024, according to data from China Insights Consultancy cited in the IPO application. The report also described Epiworld as the first company to mass-produce the more advanced 8-inch SiC epitaxial wafers.
The company enjoyed explosive growth until last year. It sold 85,400 SiC wafers in 2022, rising to 200,600 the following year and dipping again to 164,400 in 2024, according to its earnings reports. More than 95% of the sales came from 6-inch SiC wafers, with 8-inch wafers making up the rest.
Tianyu Semiconductor, as we&nbsp;<a href="https://thebambooworks.com/tianyu-semiconductor-seeks-ipo-cash-infusion-in-turbulent-market/">reported</a>&nbsp;a few months ago, is also a SiC specialist seeking a Hong Kong IPO. The company sold 132,000 SiC epitaxial wafers in 2023, 68,600 fewer than Epiworld. In the 8-inch segment, Tianyu sold 15 units compared with Epiworld's 285 that year. Epiworld boosted its 8-inch sales to 7,466 units last year.
As for earnings, Epiworld's revenues came in at 441 million yuan ($60.21 million) in 2022 and surged to 1.14 billion yuan in 2023, before falling 14.8% to 974 million yuan last year.&nbsp;
The drop was blamed on falling prices of SiC epitaxial wafers, after production capacity in the industry surged over several years, creating a serious supply glut in 2024. The price of 6-inch SiC substrate fell sharply, weighing on the price of epitaxial wafers.
The unit price of 6-inch SiC epitaxial wafers dropped from 11,400 yuan to 9,800 yuan between 2020 and 2023, falling another 25.5% to 7,300 yuan in 2024. With tumbling prices, the company's gross margin sank from 44.7% in 2022 to 34.1% in 2024.
<h4 class="wp-block-heading">Drop in consignment business</h4>
Revenue from consignment contracts, in which wafers are manufactured using a customer's raw materials, was particularly hard hit. Consignment orders only brought in 121 million yuan in 2024, a year-on-year drop of nearly 59%, taking the share of total turnover from 35.5% in 2022 to 12.4% last year.
Production on behalf of third parties is a declining model, as the global SiC market shifts to an integrated solution in which multinational manufacturers such as&nbsp;Wolfspeed&nbsp;(WOLF.US) and&nbsp;Infineon&nbsp;(IFX.DE) operate end-to-end production. At the same time, leading Chinese companies such as&nbsp;BYD&nbsp;(1211.HK; 002594.SZ) and&nbsp;Sanan Optoelectronics(600703.SH) have begun to build their own epitaxial wafer facilities, taking business away from independent wafer makers.
The escalating trade war as the United States unleashes a barrage of tariffs is also casting a shadow, as Epiworld is heavily dependent on overseas customers, who accounted for 766 million yuan of revenue last year, nearly 79% of the total turnover. Potential risks to its business highlighted in the prospectus include geopolitical tensions, international trade policies, international export controls and economic sanctions.
<h4 class="wp-block-heading">Heavily subsidized</h4>
Despite falling revenue and gross margin, the company still managed to increase its net profit last year, which grew 36% to 166 million yuan, mostly due to increased government subsidies.
Building a thriving industry in advanced microchips is one of China's strategic priorities, seen as key to leapfrogging foreign peers. To achieve that end, state support has been extended at several levels, with Epiworld alone securing 13.51 million yuan, 47.35 million yuan and 112 million yuan over the past three years. In 2024, government subsidies were equivalent to 67.5% of its net profit.
Epiworld has completed multiple financing rounds since its inception, with backers such as Huawei-owned Hubble Technology,&nbsp;China Resources Microelectronics&nbsp;(688396.SH), Xincheng Zhongchuang, Xiamen Hi-Tech Investment and Xiamen Torch Capital. Last December it raised 1 billion yuan with the help of the Xiamen State-owned Asset Supervision and Administration Commission, securing a valuation of 26 billion yuan.
The company has grown into a global leader in SiC epitaxial wafers, but now faces industry consolidation, falling prices and the risk of increasingly polarized global trade. Still, it can count on state support as China invests in building its own microchip ecosystem. Shares in InnoScience, a Hong Kong-listed industry peer, have surged as much as 110% since its IPO and are still trading more than 30% above the listing price.
With relatively few listed Chinese companies in this space, Epiworld could still get a warm reception from investors.

Asia

Earnings

IPOs

Opinion

Chinese Foundry Files For Hong Kong IPO Amid Falling Wafer Prices

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Benjamin Swinburne downgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Overweight to Equal-Weight and lowered the price target from $37 to $32. Warner Music shares closed at $29.12 on Thursday. <a href="https://www.benzinga.com/quote/wmg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Craig Ellis downgraded the rating for Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) from Buy to Neutral and cut the price target from $80 to $50. Axcelis Technologies shares closed at $44.78 on Thursday. <a href="https://www.benzinga.com/quote/acls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Josh Beck downgraded Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) from Strong Buy to Outperform and lowered the price target from $275 to $195. Amazon.com shares closed at $172.63 on Thursday. <a href="https://www.benzinga.com/quote/amzn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Gil Luria downgraded the rating for Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Neutral to Underperform and announced a $200 price target. Salesforce shares closed at $247.26 on Thursday. <a href="https://www.benzinga.com/quote/crm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst John Aiken downgraded Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Buy to Hold and slashed the price target from C$100 to C$89.  <a href="https://www.benzinga.com/quote/CM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CRM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21082113/image-1-15-1024x587.png" alt="" class="wp-image-879587" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21082113/image-1-15-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21082113/image-1-15-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21082113/image-1-15-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21082113/image-1-15.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Downgrades

ACLS

AMZN

TSX:CM

This Salesforce Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Seaport Global analyst Michael Harrison maintains Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) with a Buy and lowers the price target from $195 to $160.

Seaport Global Maintains Buy on Quaker Houghton, Lowers Price Target to $160

Venu Holding Corporation ("VENU" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VENU#NYSE">VENU</a>), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, announced today that J.W. Roth, Founder, Chairman, and CEO will present VENU's once-in-a-lifetime opportunity to investors on Tuesday, April 22nd, 2025, at President Trump's Mar-a-Lago Club in Palm Beach, Florida.

Events

VENU

Venu's J.W. Roth, Founder, Chairman, And CEO Will Present At President Trump's Mar-a-Lago Club In Palm Beach, Florida  On April 22nd, 2025

Avoid AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>). That&#8217;s the advice from Jim Cramer on the latest edition of CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>.&#8221;
&#8220;[AMC] should have reorganized by now, and they haven&#8217;t,&#8221; Cramer said. &#8220;They have way <a href="https://www.benzinga.com/quote/amc/analyst-ratings">too much debt.&#8221;</a>
Supporting his view, Roth MKM analyst Eric Handler, on April 16, maintained AMC Entertainment with a Neutral rating and lowered the price target from $3.25 to $3.
Cramer recommended to sell Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>).
As per the recent news, Cal-Maine Foods, on April 8, reported worse-than-expected third-quarter revenue results. Additionally, the company announced the acquisition of Echo Lake Foods for approximately $258 million and stated it is cooperating with a civil investigative demand by the DOJ into the nationwide increase in egg prices.
&#8220;I'm going to say absolutely no to that one,&#8221; Cramer said when asked about Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>).
Webull shares fell sharply on Thursday extending a volatile first week of public trading following its SPAC merger with SK Growth Opportunities. 
A Fox Business's Charles Gasparino report indicated that U.S. lawmakers are pushing the SEC to investigate Webull's Chinese ties and potentially move toward delisting the brokerage.
Price Action:
<ul>
<li>AMC shares fell 0.7% to settle at $2.78 on Thursday.</li>
<li>Cal-Maine Foods shares fell 1.1% to close at $91.49 during the session.</li>
<li>Webull shares dipped 27.3% to settle at $26.33 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

BULL

CALM

Jim Cramer Recommends Staying Away From AMC, Says 'Absolutely No' To Webull

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $32 price target.

CMPX

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Sohu.com Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>)</h3>
<ul>
<li>On Feb. 18, Sohu.com posted a non-GAAP net loss of $15 million for the fourth quarter, versus a year-ago loss of $11 million. Total revenues fell 5% year-over-year to $135 million. Dr. Charles Zhang, Chairman and CEO of Sohu.com Limited, commented, &#8220;In the fourth quarter of 2024, our brand advertising revenues hit the high end of our previous guidance, while both our online game revenues and bottom line performance were much better than expected. For Sohu media platform, we continued to refine our products, optimized algorithms, and strictly controlled budgets.&#8221; The company's stock fell around 41% over the past month and has a 52-week low of $7.79.</li>
<li>RSI Value: 19.3</li>
<li>SOHU Price Action: Shares of Sohu gained 5.3% to close at $8.33 on Thursday.</li>
<li>Edge Stock Ratings: 17.24 Momentum score with Value at 91.56. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/SOHU"><img loading="lazy" decoding="async" width="496" height="196" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023415/image-1-12.png" alt="" class="wp-image-878989" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023415/image-1-12.png 496w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023415/image-1-12-300x119.png 300w" sizes="(max-width: 496px) 100vw, 496px" /></a></figure>
<h3 class="wp-block-heading">IAC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>IAC will post its first quarter results after the closing bell on Monday, May 5. The company's stock fell around 17% over the past month and <a href="https://www.benzinga.com/quote/IAC">has a 52-week low</a> of $32.08.</li>
<li>RSI Value: 28.7</li>
<li>IAC Price Action: Shares of IAC gained 0.8% to close at $33.02 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">IAC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="923" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023523/image-29.png" alt="" class="wp-image-878992" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023523/image-29.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023523/image-29-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023523/image-29-768x705.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Integral Ad Science Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>)</h3>
<ul>
<li>On April 17, Morgan Stanley analyst Matthew Cost maintained Integral Ad Science with an Equal-Weight rating and lowered the price target from $13.5 to $12.5. The company's stock fell around 28% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/IAS">low of $6.32.</a></li>
<li>RSI Value: 28.4</li>
<li>IAS Price Action: Shares of Integral Ad Science gained 1.7% to close at $6.52 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">breakout in IAS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="898" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023739/image-30.png" alt="" class="wp-image-879000" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023739/image-30.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023739/image-30-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21023739/image-30-768x725.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

SOHU

Top 3 Tech And Telcom Stocks That Are Preparing To Pump In Q2

D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) with a Buy and maintains $14 price target.

MDCX

D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $14 Price Target

The U.S. Dollar Index Spot slipped below 98 points for the first time in over three years on Monday, while the 10-year Treasury yields were steady around 4.35%. Experts describe this divergence as the measure of stress in markets."
What Happened: The U.S. Dollar Index slipped 1.20% to 98.211 during the publication of this article. However, its day range stood between 97.921 — 99.208 on Monday, according to the TradingView data.
Historical data shows that the dollar index last slipped below the 98 point mark to 97.79 as of March 30, 2022, closing. Whereas, the 10-year Treasury bond yielded 4.35%.
Jim Bianco, the president and founder of Bianco Research LLC., highlighted this divergence in an X post and called it a "measure of stress in markets."
"Higher rates are not supporting the dollar right now. This means they might have to go a lot higher to stop the dollar from falling," he added.
The relationship between higher yields and higher dollar value exists because the dollar value generally appreciates when foreign investors buy U.S. dollar-denominated instruments, especially the risk-free Treasury bonds. However, this divergence, as shared by Bianco in the given chart, raises concerns.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">1/2 The breaking of this relationship is a measure of stress in markets &#8230; it continues to widen.(Higher rates are not supporting the dollar right now. This means they might have to go a lot higher to stop the dollar from falling.) <a href="https://t.co/PRj6mYNu0J">pic.twitter.com/PRj6mYNu0J</a>
&mdash; Jim Bianco (@biancoresearch) <a href="https://twitter.com/biancoresearch/status/1914160730535756287?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, economist Peter Schiff underscored that the dollar was 11% lower since President Donald Trump's inauguration day and 6% since the "so-called" Liberation Day, when the reciprocal tariffs against the U.S. trading partners were announced.
"Trump&#8217;s economic team assured us that foreigners would pay our tariffs, in part because their currencies would fall against the dollar. Instead, a collapsing dollar adds to our cost," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The U.S. Dollar Index has a 97 handle, down 11% since Trump took office (6% since Liberation Day.) Trump&#39;s economic team assured us that foreigners would pay our tariffs, in part because their currencies would fall against the dollar. Instead a collapsing dollar adds to our cost.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1914249859353264212?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/global/25/04/44891949/xi-jinpings-china-pledges-retaliation-against-countries-isolating-beijing-by-giving-into-trump-admini">Xi Jinping&#8217;s China Pledges Retaliation Against Countries Isolating Beijing By Giving Into Trump Administration&#8217;s &#8216;Unilateral Bullying,&#8217; Says It Will &#8216;Never Accept It&#8217;</a>
Why It Matters: Additionally, a recent study released last week, titled ‘<a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-curren">Dollar Upheaval: This Time is Different</a>,' highlights that "Between April 4 and April 14, the U.S. dollar depreciated by 3.6%." 
"Normally, in times of global volatility… the dollar appreciates as dollar-denominated assets benefit from a flight to safety. Not this time around," the note stated.
The dollar&#8217;s surprising depreciation indicates a divergence from typical market behavior. "If U.S. Treasuries are no longer viewed as the world&#8217;s preferred safe asset, then the status of the dollar as the world&#8217;s reserve currency may be called into question," the note stated.
Meanwhile, Chatham House expert David Lubin highlighted in another note that "policy push" from Trump's administration aims to weaken the dollar permanently against other currencies,
"Undermining the dollar&#8217;s global status would not only transmit huge amounts of additional uncertainty to the global economy, but would be a needless act of self-harm for the U.S.," cautioned Lubin.
Price Action: The dollar index was down 9.49% on a year-to-date basis. The WisdomTree Bloomberg US Dollar Bullish Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USDU#NYSE">USDU</a>) was 5.82% YTD, whereas, Invesco DB US Dollar Index Bullish Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) dropped 7.99% in 2025.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 1.32% to $519.46, while the QQQ declined 1.54% to $437.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44892375/dean-of-valuation-aswath-damodaran-warns-buying-the-dip-akin-to-catching-a-falling-">Dean Of Valuation Aswath Damodaran Warns Buying The Dip Akin To Catching A Falling Knife, Says It Takes A &#8216;Stronger Stomach&#8217; Than Most Have</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Currency ETFs

Forex

Economics

ETFs

General

USDU

PowerShares DB US Dollar Index Bullish Fund

Dollar Slips To A Three-Year Low Below 98-Mark: 'Higher Rates Are Not Supporting The Dollar,' Says Expert

Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) (Excelerate or the Company) today reported preliminary estimated financial results for the first quarter ended March 31, 2025.
PRELIMINARY ESTIMATED Q1 2025 FINANCIAL RESULTS
<ul>
<li>Income before taxes expected to be in the range of $52-59 million for the first quarter</li>
<li>Adjusted EBITDA expected to be in the range of $96-101 million for the first quarter</li>
<li>Cash and cash equivalents expected to be between $600-620 million as of March 31, 2025, which does not include approximately $175.5 million of net proceeds received on April 2, 2025 from the Company's public offering of Class A common stock</li>
<li>All $350 million of the Revolving Credit Facility was undrawn and available for borrowing as of March 31, 2025</li>
</ul>

CORRECTION: Excelerate Energy Expects Q1 Adj. EBITDA To Be $96M-$101M; Sees Q1 Income Before Taxes Between $52M-$59M

DA Davidson analyst Gil Luria downgrades Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Neutral to Underperform and announces $200 price target.

DA Davidson Downgrades Salesforce to Underperform, Announces $200 Price Target

Date: 21.04.2025&nbsp; Press Release No. 10/2025-26&nbsp; CCI Approves Google's Settlement Proposal in Android TV Case&nbsp; 1. The Competition Commission of India (Commission), in terms of Section&nbsp; 48A (3) of the Competition Act, 2002 (the 'Act'), and the Competition&nbsp; Commission of India (Settlement) Regulations, 2024 (‘Settlement&nbsp; Regulations'), vide majority order, has agreed to the Settlement Proposal&nbsp; of Google in the Android TV case.&nbsp; 2. The case originated from the Information filed by two individuals, namely&nbsp; Mr. Kshitiz Arya and Mr. Purushottam Anand under Section 19(1)(a) of&nbsp; the Act, 2002 against Google LLC, Google India Private Limited, Xiaomi&nbsp; Technology India Private Limited and TCL India Holding Private Limited&nbsp; for alleged contravention of various provisions of the Act.&nbsp; 3. The gist of the allegation was that Google misused its dominant position&nbsp; by enforcing restrictive agreements on OEMs, including compulsory&nbsp; bundling of the Play Store with Android TV OS and preventing the use or&nbsp; creation of rival forked Android versions through its Anti-Fragmentation&nbsp; Agreements. These practices allegedly blocked market access, curbed&nbsp; competition, and placed unrelated obligations on Original Equipment&nbsp; Manufacturers (‘OEMs'), ultimately stifling innovation and violating&nbsp; provisions of Section 4 of the Act.&nbsp; &nbsp;
 2&nbsp; 4. The Commission formed a prima facie view that Google has contravened&nbsp; various provisions of Sections 3(4) and 4 of the Act and directed the DG&nbsp; to cause an investigation to be made under the provisions of Section 26(1)&nbsp; of the Act.&nbsp; 5. The investigation concluded that Android Smart TV OS has a dominant&nbsp; position in the relevant market of ‘licensable Smart TV device operating&nbsp; system in India' and Google Play Store is in a dominant position in the&nbsp; ‘Market for App Store for Android Smart TV OS in India'. It found that&nbsp; Google's agreements—Television App Distribution Agreement (‘TADA') and&nbsp; Android Compatibility Commitments (‘ACC')—executed together, imposed&nbsp; unfair terms by requiring the pre-installation of its full app bundle Google&nbsp; TV Services, preventing OEMs from developing or using Android forks,&nbsp; and hindering innovation. These agreements extended across entire&nbsp; device portfolios and included the tying of services like YouTube with the&nbsp; Play Store, strengthening Google's market dominance and breaching&nbsp; several provisions of Section 4 of the Act. The allegation of refusal to deal&nbsp; and exclusive supply under Section 3(4) was not substantiated.&nbsp; 6. Google filed a Settlement Application under Section 48A of the Act, read&nbsp; with the Settlement Regulations. The Commission invited objections and&nbsp; suggestions in terms of regulation 5 of the Settlement Regulations on the&nbsp; settlement proposal from 45 concerned parties. The Commission&nbsp; considered the settlement proposal and observed that under the "New&nbsp; India Agreement," Google will provide a standalone license for the Play&nbsp; Store and Play Services for Android smart TVs in India, thereby removing&nbsp; the requirement to bundle these services or impose default placement
 3&nbsp; conditions. Additionally, by waiving the need for a valid ACC for devices&nbsp; shipped into India that do not include Google apps, OEMs can now sell&nbsp; and develop incompatible Android devices without violating the TADA.&nbsp; 7. Consequently, considering the material on record and the assessment of&nbsp; the Settlement Proposal after taking into consideration the nature, gravity,&nbsp; and impact of the contraventions, the Commission agrees to the proposal&nbsp; for settlement in terms of Section 48A (3) of the Act and the Settlement&nbsp; Regulations. The Final Settlement Amount, after applying a Settlement&nbsp; Discount of 15%, is Rs. 20.24 crore.&nbsp; 8. A copy of the public version of the order passed is available on the CCI&nbsp; website at <a href="https://www.cci.gov.in/antitrust/orders/details/1182/0. " title="https://www.cci.gov.in/antitrust/orders/details/1182/0. ">https://www.cci.gov.in/antitrust/orders/details/1182/0. </a> &#x2A;&#x2A;&#x2A;&#x2A;&#x2A;&#x2A;&#x2A;
 &nbsp;

Legal

GOOG

GOOGL

Competition Commission Of India Approves Google's Settlement Proposal In Android TV Case

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1.png" alt="" class="wp-image-11031" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The operator of the Tim Hortons chain in China sold 22 million bagel-based products last year, and said it is aiming to return to revenue and same-store sales growth in 2025
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>TH International's revenue fell 12% in the fourth quarter, moderating from a 17% decline in the previous quarter</li>
<li>The company is targeting a return to revenue growth and achieving breakeven on an EBITDA basis this year</li>
</ul>
The Tim Hortons chain was historically known for donuts, founded in 1964 by its namesake former ice hockey star who also presumably loved the sugary snack. But after yanking the company's core product from most of its menus, the company's China iteration, Tims China, has found better results with bagels, which look similar but lack the sweetness.
Tims China operator&nbsp;TH International Ltd.&nbsp;(THCH.US) has had it rough lately, struggling to differentiate itself from a crowded and fiercely competitive field of premium coffee sellers including everyone from&nbsp;Starbucks&nbsp;(SBUX.US) to local sensations&nbsp;Luckin&nbsp;(LKCNY.US) and&nbsp;Cotti. But the company may have finally found its answer in bagels, based on its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/04/15/3061592/0/en/Tims-China-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html">latest financial report</a>&nbsp;that mentions the bread-based Western staple numerous times and shows that Tims China may have finally turned a corner in the fourth quarter.
The company said it sold 22 million bagel and bagel sandwich products last year, which averages more than 60 sales per day for each of its roughly 950 stores during the year – not bad for this relatively new differentiator.
Investors seemed to like the chain's new China flavor, sending the company's embattled stock up 18% in three trading days after the announcement this week. Still, the stock has lost about half of its value over the last year and currently trades at a watered-down price-to-sales (P/S) ratio of just 0.45. By comparison, Luckin and&nbsp;Yum China&nbsp;(YUMC.US; 9987.HK), which is also moving aggressively into premium coffee, trade at much higher multiples of 2.08 and 1.52, respectively.
In addition to finding success in bagels, which it serves not only with traditional toppings like cream cheese, but also as a bread substitute for various sandwich-type products, TH International has also found better results with franchising than self-operated stores. That's different from most other restaurant operators, whose self-operated stores are typically more profitable, but choose to also use franchising to expand more quickly and conserve capital.
CFO Li Dong said TH International's franchise business currently contributes "steady cash flows and profitability," even as the company's self-operated stores continue to lose money, resulting in overall operating losses.
As its situation improves, the company is also holding out big hopes for 2025. It is targeting a return to same-store sales and revenue growth, after the important metrics turned negative in early 2024 and remained that way for the rest of the year. It is also aiming to achieve breakeven on an earnings before interest, taxes, depreciation and amortization (EBITDA) basis for all of 2025, which would represent the first time a major profit metric wasn't negative.
"Moving into the spring of 2025, we look forward to regaining growth on our top line and to continue our expansion with plans to open at least 200 stores this year, the majority of which will be through our successful subfranchise (business) while maintaining our focus on operational excellence and profitability," said CEO Lu Yongchen.
<h4 class="wp-block-heading">Third-quarter bottom</h4>
Broadly speaking, TH International's latest results show the company's recent downturn bottomed out in last year's third quarter and it began recovering at the end of the year as it completed some major adjustments to its self-operated stores and its franchise business gained momentum. Its revenue fell 12% to 333 million yuan ($45.6 million) during the quarter from 378 million yuan a year earlier, improving from a 17% decline in the previous quarter.
The story was similar for the company's same-store sales, whose 13.3% decline in the fourth quarter represented an improvement from the 21.7% decline in the third quarter.
The company passed a symbolic milestone during the fourth quarter as it opened its 1,000th&nbsp;store in Shanghai, bringing its total to 1,022 by the end of last year. Six years after coming to China, TH International has a relatively large footprint in the country, with stores in 82 cities.
A deeper dive into the overall store count figure shows the company was aggressively closing underperforming self-operated stores during the first three quarters of last year, with the figure dropping from 619 at the end of 2023 to 564 at the end of last September. But the trend returned to a positive direction in the fourth quarter, as its self-operated store count rose to 576 at the end of last year.
Meantime, the company's franchised store count has grown steadily without pause, rising from 283 at the end of 2023 to 446 at the end of last year, making up 44% of its total. And as we've previously noted, CEO Lu said a majority of the new store openings this year will come from the franchised business, though he wasn't more specific.
While the franchised business is more profitable and looks on track to overtake the company's self-operated stores in terms of store count, the former contributes far less revenue than the latter. TH International said its self-operated stores generated 270 million yuan in the fourth quarter, down 17.7% year-on-year, but still making up 81% of its total. By comparison, its "other revenue," which comes mostly from the franchised store business, rose 25.8% year-on-year during the fourth quarter to 62.5 million yuan, even though it made up just 19% of its total.
The company has also been relatively strong in terms of cost controls, with store costs and expenses down 18.8% year-on-year in the fourth quarter, and marketing expenses down by an even larger 35%.
The combination of cost controls, closure of underperforming stores and new success with its bagel-based formula helped TH International narrow its operating loss to 117 million yuan from 218 million yuan a year earlier, and reduce its net loss to 132 million yuan from 311 million yuan over that time. CFO Li also noted the company is "no longer cash burning like in the past years," and that it has ample funds after receiving new financing from its founding shareholders.
All those signals seem to show that TH International may be emerging from a difficult period as a more focused company that can operate profitably in the not-too-distant future. Now, it just needs to show it can maintain its recent positive momentum in the face of fierce competition and headwinds created by China's slowing economy.

Equities

Restaurants

THCH

Tim Hortons China Operator Finds Gamechanger In Bagels

Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) ("Excelerate" or the "Company") today announced that Excelerate Energy Limited Partnership (the "Issuer"), a subsidiary of Excelerate, has commenced an offering (the "Offering") of $700 million in aggregate principal amount of unsecured senior notes due 2030 (the "2030 Notes"). Excelerate intends to use the net proceeds from the Offering, together with the net proceeds from the equity offering previously consummated by the Company and cash on hand, to (i) fund the consideration payable by the Company in the previously-announced pending acquisition of New Fortress Energy, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) business in Jamaica for $1.055 billion, subject to certain adjustments, (ii) repay the outstanding borrowings under the Company's term loan facility, which were $163.6 million as of December 31, 2024, and (iii) pay related fees and expenses.
The 2030 Notes will be guaranteed by certain direct and indirect restricted subsidiaries of the Issuer.

Offerings

Excelerate Energy Announces Proposed Offering Of $700M Of Senior Notes Due 2030

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&nbsp;disclosed in its 2024 annual report last week that the <a target="_blank" href="https://www.benzinga.com/topic/tsm" rel="noreferrer noopener">U.S. semiconductor technology</a> embargo challenged its ability to ensure complete compliance with the rules.
The Taiwanese contract chipmaker also held the semiconductor sanctions responsible for leading to higher violations of semiconductor sanctions by business partners to gain access to <a target="_blank" href="https://investor.tsmc.com/english/annual-reports" rel="noreferrer noopener">the advanced technology</a>.
Taiwan Semiconductor disclosed it could not guarantee complete compliance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst" rel="noreferrer noopener">These Semiconductor Stocks To Face Least Tariffs Impact Compared To Intel</a>
Taiwan Semiconductor partners&nbsp;Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)&nbsp;and&nbsp;MediaTek Inc co-developed mobile chips for phone makers, including&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), as per a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-21/tsmc-warns-of-limits-of-ability-to-keep-its-ai-chips-from-china?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">report</a>. However, a 2024 report by TechInsights&nbsp;revealed&nbsp;the presence of Taiwan Semiconductor technology in Huawei Technology&#8217;s Ascend 910B AI chip.
The U.S. has restricted Huawei&#8217;s access to advanced semiconductor technology since 2020, citing national security threats.
Taiwan Semiconductor disclosed in its annual report that it took every precaution, including restricting shipment to its trading partners, to ensure compliance with the U.S. sanctions.
Taiwan Semiconductor&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">first-quarter revenue</a> rose 41.6% to $25.53 billion, topping the analyst consensus estimate of $23.92 billion, despite a smartphone seasonality impact on sales.
The second-quarter revenue guidance predicts $28.4 billion-$29.2 billion versus the $26.79&nbsp;billion analyst estimate, with strong demand for 3-nm and 5-nm technologies.
In March, Taiwan Semiconductor announced&nbsp;an additional&nbsp;$100 billion&nbsp;investment&nbsp;in U.S. chipmaking (on top of $65 billion in April 2024). The investment followed&nbsp;President Donald Trump&#8217;s verbal attacks&nbsp;on Taiwan &#8220;for stealing&#8221; the U.S. semiconductor business and generating massive trade deficits for Washington.
Price Action:&nbsp;TSM stock is down by 1.91% to $148.85 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44851295/asml-cfo-incorporates-tariff-impact-in-outlook-reveals-strong-demand-for-advanced-euv-and-high-na-systems" target="_blank" rel="noreferrer noopener">ASML CFO Incorporates Tariff Impact In Outlook, Reveals Strong Demand For Advanced EUV And High NA Systems</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Tech

QCOM

XIACF

XIACY

Taiwan Semiconductor Confronts Challenges Of US Chips Sanction On China

Native health advocates are raising alarms over a proposed federal budget that reduces funding to the Indian Health Service (IHS). In a letter dated April 17 sent to the Health and Human Services Secretary Robert F. Kennedy, Jr., the National Indian Health Board (NIHB) criticized the planned cuts as dangerous and urged urgent rectification.
What Happened: The Office of Management and Budget's (OMB) proposed adjustments include almost a 30% reduction to the IHS base budget from FY 2025 estimates, amounting to approximately $900 million in cuts for FY 2026. The plan also removes advance appropriations, stops funding for water and sanitation and healthcare facility construction, restricts self-governance for new Tribes, and eradicates services across the board.
"We implore you to immediately appeal the proposed reductions… mirroring the swift and decisive action taken by the Secretary of the Interior," the NIHB urged <a href="https://ncuih.org/2025/04/18/ncuih-urges-hhs-to-reconsider-proposed-budget-cuts-to-indian-health-service-and-hhs/">in the letter</a>.
See Also: <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">RFK Jr. To Cut 10,000 Jobs, Shut Regional Agencies In Major Health Department Overhaul: Report</a>
Why It Matters: The IHS operates with a 30% vacancy rate at the moment, the letter states. It adds: "if each facility across the IHS lost just one physician-level provider, 43% of those facilities would have to close their doors entirely."
The letter calls the proposed cuts as a direct threat to life. "This loss of funding will lead to deaths in our communities from preventable medical incidents, such as precipitous births, cardiac events, untreated diabetes complications, and preventable suicides," it warns.
The NIHB clarifies that these are not hypotheticals—they are documented outcomes from past underfunding. "Before IHS had advance appropriations… members of our families died from these exact types of preventable emergencies," the letter said.
Secretary Kennedy has previously said Indian health is a top priority. With more than 574 federally recognized Tribal Nations relying on IHS, the NIHB is calling on him to that stay true to that promise by declining the OMB's proposed reductions.
"The funding to the IHS is not an arbitrary budget number," the NIHB wrote. "These figures represent funding to keep doctors and nurses in our facilities nationwide."
Kennedy Jr.&#8217;s <a href="https://www.benzinga.com/25/04/44782857/rfk-jrs-massive-federal-health-workforce-cut-could-take-decades-to-rebuild-warn-experts-we-cannot-accurately-assess-whether-we-are-truly-making-america-healthier">mass layoffs have concerned experts</a>, disrupting crucial health data collection and research, including studies on cancer in firefighters and the transmission of HIV and syphilis from mothers to babies. Attempts to monitor and contain disease outbreaks—like the country&#8217;s worst measles outbreak in decades—have also been impacted.
Earlier this month, Kennedy <a href="https://www.benzinga.com/25/04/44777309/health-secretary-kennedy-raises-concerns-about-taxpayer-funded-care-for-risky-behaviors">stirred controversy</a> in an interview with CBS News, where he asked whether taxpayers should foot the bill for those who smoke regularly or often eat unhealthy foods, like doughnuts.
Read Next: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-p">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Image Via Shutterstock

Health Care

Native Health Leaders Slam Trump Administration's Proposed $900 Million Cuts To Indian Health Service: Call Plan 'Dangerous' In Letter To RFK Jr.

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented&nbsp;
Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is being held May 30 - June 3, 2025, in Chicago, Illinois and virtually. IMUNON recently announced alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation.
IMNN-001, based on the company's proprietary TheraPlas&#xAE; technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (Stage III/IV) ovarian cancer.
"We are pleased to have the opportunity to present new data from the Phase 2 OVATION 2 Study of IMNN-001 in an oral presentation at ASCO's Annual Meeting," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "This recognition underscores the significant potential of IMNN-001 to transform the treatment of women with newly diagnosed advanced ovarian cancer, an underserved population that has not seen treatment innovation in over 25 years, as we advance our Phase 3 program. We look forward to sharing more about our progress during this pivotal stage of development."
Details for the oral presentation are as follows:
Presentation Details
Title: A Phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer (EOC): Updated survival analysts from OVATION-2 trial
Session Title: Rapid Oral Abstract – Gynecologic Cancer
Session Date: June 3, 2025
Session Time: 8:00 AM-9:30 AM CDT

Biotech

IMNN

Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical Oncology Annual Meeting May 30 - June 3, 2025, In Chicago, Illinois

Commodities

Press Releases

Chord Energy Reports Second Quarter 2024 Financial and Operating Results, Declares Base and Variable Dividends and Issues an Updated Outlook

Chord Energy Releases 2023 Sustainability Report

Chord Energy Schedules Third Quarter 2024 Earnings Release and Conference Call

Chord Energy Reports Strong Third Quarter 2024 Financial and Operating Results, $146MM of Share Repurchases and Issues 2025 - 2027 Outlook

Chord Energy Schedules Fourth Quarter and Year End 2024 Earnings Release and Conference Call

Chord Energy Reports Strong Fourth Quarter and Full-Year 2024 Financial and Operating Results, Issues 2025 Outlook and Increases Base Dividend

Chord Energy Corporation Announces $750 Million Offering of Senior Notes

CHORD ENERGY CORPORATION ANNOUNCES A CASH TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING 6.375% SENIOR NOTES DUE 2026

Chord Energy Corporation Announces Pricing of $750 Million Offering of Senior Notes

Chord Energy Corporation Announces Pricing of Cash Tender Offer for Any and All of its Outstanding 6.375% Senior Notes Due 2026

Antero Resources Corporation Common Stock

Antero Resources

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

CNX Resources

ConocoPhillips

California Resources Corporation Common Stock

California Resources

Comstock Resources

Coterra Energy

Devon Energy

EOG Resources

Expand Energy

Diamondback Energy

Gulfport Energy Corporation Common Shares

Gulfport Energy

Hess

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Matador Resources

Ovintiv

Permian Resources Corporation Class A Common Stock

Permian Resources

Range Resources

Texas Pacific Land Corporation Common Stock

Texas Pacific Land

Venture Global, Inc. Class A common stock

Venture Global

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Vista Energy

Viper Energy, Inc. - Class A Common Stock

Viper Energy

Woodside Energy Group Limited American Depositary Shares, each representing one Ordinary Share

Comments

Chord Energy

Noticias

Últimas noticias sobre Chord Energy (NASDAQ:CHRD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL